As we welcome the year 2026—a year in which new challenges and opportunities coexist amid a rapidly evolving global pharmaceutical and biotechnology landscape—I extend my sincere wishes for your continued health and well-being. I would also like to express my deepest gratitude to all members for their dedication and contributions to the growth and advancement of KSPST over the past year.

Since its establishment in 1971, KSPST has grown into a leading academic society, advancing pharmaceutical sciences and strengthening the competitiveness of the pharmaceutical and biotechnology industries for more than half a century. Building on strong academic foundations, expanded international exchange, and close collaboration with industry, KSPST has continuously worked to ensure that research outcomes translate into industrial, clinical, and social value. Through diverse academic activities including the Science Month Symposium, Pharmaceutical Technology Workshop, International Conference of KSPST and CRS Korea Local Chapter activities, KSPST has served as a bridge connecting research with industry and clinical practice. In addition, the official journal, Journal of Pharmaceutical Investigation, has continued to achieve qualitative advancement and to strengthen its international standing since its inclusion in the SCIE, thanks to the outstanding research achievements and dedicated participation of our members.

Today, the pharmaceutical and biotechnology industries are experiencing rapid technological innovation in areas such as mRNA-based therapeutics, gene and cell therapies, antibodies and ADCs, digital therapeutics, AI-driven drug discovery, and advanced drug delivery systems. At the same time, these advances are accompanied by increasing regulatory complexity, rising development costs, and intensified global competition. In response, KSPST will further strengthen collaboration among academia, industry, research institutes, and regulatory authorities, and will reinforce its role as a practical R&D linkage platform spanning basic research, formulation design, delivery technologies, manufacturing, and regulatory science. Through these efforts, KSPST aims to accelerate the development of innovative medicines and to provide a forum for rational regulatory discussions grounded in scientific evidence, thereby contributing to a virtuous cycle in which research outcomes extend to industry and society.

In 2026, the executive committee of KSPST remains committed to responding proactively to this era of change through robust academic activities and strategic expansion, while building a KSPST that grows together with its members and leads future pharmaceutical technologies. I sincerely appreciate your continued interest and active participation as we pursue the next leap forward of KSPST. Together, let us build KSPST in which all members take pride, and in which the value of research extends meaningfully to society.

Sincerely yours,